Mergers & Acquisitions Mergers & Acquisitions

Hapvida-Plamed deal shouldn't be approved as is, Brazilian antitrust investigators say

By Ana Paula Candil
  • 27 Jul 2022 20:17
  • 27 Jul 2022 20:17
Healthcare plan operator Hapvida's planned purchase of certain assets from rival Plamed shouldn't be approved as is, Brazilian antitrust investigators said in an opinion.

The case will be referred to the governing Tribunal of the Administrative Council for Economic Defense, or CADE, for a definitive ruling. The opinion from the agency's Superintendence isn't

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

TAKE A FREE TRIAL

Latest News